Raydiant Oximetry key facts
as of Oct 2026- Developer of a non-invasive medical device designed to deliver healthy babies and prevent cesarean section issues.
- Raydiant Oximetry is valued at approximately $27.0M as of Oct 2026, set at its later-stage round, Feb 2026; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $62.3M across 6 recorded rounds; the latest was Seed Round ($4.3M) in May 2024.
- Notable investors include US National Science Foundation, Enterprise Ireland, Impact Assets, MedTech Innovator, StartX (US) — 38 tracked in total.
- Raydiant Oximetry has filed 9 Form Ds with the SEC since 2018, most recently Jun 2024 ($4.3M sold to 32 investors).
- Status: Privately Held (backing).
Valued at $27.0M at its later-stage round, Feb 2026. Nothing has traded since.
- ·The complete investor list: 38 names
- ·Watch Raydiant Oximetry: the Monday email on marks, rounds and moves
Raydiant Oximetry funding rounds
6 roundsWho backs Raydiant Oximetry
38+Raydiant Oximetry valuation
Raydiant Oximetry was valued at $27 million at its later-stage round in Feb 2026. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Raydiant Oximetry raised?
Raydiant Oximetry has raised $62.3 million in total; 6 of its rounds are on record, from 2018 on. The largest on record was a $993,000 debt round in Feb 2018; the most recent was a $4.3 million seed round in May 2024.
Raydiant Oximetry has filed 9 Form Ds with the SEC since 2018, most recently in Jun 2024 ($4.3 million sold to 32 investors).
Raydiant Oximetry investors
38 investors are on record for Raydiant Oximetry, including US National Science Foundation, Enterprise Ireland, Impact Assets and MedTech Innovator. By type, the record holds 6 venture capital firms and 1 angel investor. The seed round in May 2024 drew 32 investors.
About Raydiant Oximetry
Developer of a non-invasive medical device designed to deliver healthy babies and prevent cesarean section issues. The company's device measures fetal oxygen levels during labor to facilitate improved outcomes for mothers and babies during childbirth and evaluates fetal oxygenation during labor, enabling clinicians to reduce the risk of birth injury and over-intervention as well as decrease healthcare costs and disparities.
- Sector
- Healthcare
- HQ
- San Ramon, CA, United States
- Founded
- 2016
- Employees
- 25
- Website
- raydiantoximetry.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.